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Introduction

Results

Discussion/Conclusion

Pancreatic Cancer is one the deadliest cancers with 6
months being the median
patient survival with
current available therapies . My current laboratory has
shown that inhibition of Eukaryotic Elongation Factor
2 kinase ( EF2K) by siRNA technology
suppresses cell proliferation of various cancer cells.
EF2K is an alpha kinase which phosphorylates
eukaryotic elongation factor 2 to create p-EF2, inhibits
EF2 function, regulates protein translation and
is
heavily involved in cell division and cell
proliferation. However, there was no clinically
applicable inhibitors of EF2K till Thymoquinone (TQ).
TQ is a compound found in Nigella Sativa that has
anti-cancer, pain relieving and anti-inflammatory and
many other capabilities. Thus, Thymoquinone is
thought to be a possible agent in fighting
cancer. However, the mechanism by which TQ
inhibits pancreatic cell proliferation has yet to
be
established.
We
hypothesize
that
TQ
suppresses
Pancreatic
Cancer
cell
proliferation through inhibition of EF2K activity. By
inhibiting EF2K activity, a dose dependent
downregulation of p-EF2 should be seen.

Clonogenic Assay

As discussed previously, the hypothesis of this
experiment was that Thymoquinone can inhibit
the proliferation of Pancreatic Cancer cells by
inhibiting EF2K activity. To prove this
hypothesis, Clonogenic assays and Western
Blots analysis were performed . The western
blot proves the inhibition of proliferation by the
EF2K pathway by showing the reduction in the
expression of p-EF2 with increasing
concentration of Thymoquinone. Additionally,
the clonogenic assay proves the hypothesis by
showing that with increasing concentration of
Thymoquinone, there is a decrease in colony
formation of the cells. This show that TQ dosedependently inhibits EF2K activity in
Pancreatic Cancer cells. These results coincide
with previous results that show that
the inhibition of EF2K gene by siRNA reduced
pancreatic cell proliferation. In conclusion, our
studies suggest that TQ inhibits pancreatic
cancer cell proliferation through EF2K activity
inhibition. These findings contribute to cancer
research by proposing an alternative drug to
treating Pancreatic Cancer. Though, there are
many more steps to go before Thymoquinone
can finally be used as a drug in fighting
Pancreatic Cancer but a few steps closer in
making cancer history.

After staining each well of the plate, it was seen that with increasing concentration of
Thymoquinone, colony formation decreased with the IC50 being 5uM of
Thymoquinone. This experiment also proves that Thymoquinone inhibits cell proliferation in
Pancreatic Cancer. These results can be seen Figure 1.

Figure 1: Duplicate Clonogenic Assay done using Panc-1 cells
and increasing concentration of Thymoquinone

Methodology
To prove the hypothesis, several clonogenic assay and
Western blots were set up in order to review the role of
Thymoquinone in inhibiting EF2K.
Western Blot
Four T-25 flasks were seeded with 10,000 Panc-1 cells,
labelled with the concentrations of thymoquinone they
were to be treated with and left to proliferate and attach to
the flask for 48 hours. After 48 hours, treatments of
Thymoquinone were added to the flasks. The
concentratiions were as follows 2.5uM, 5uM and 10uM
with control, DMSO. After the treatment was added, the
cells were left for another 48 hours. After 48 hours, the
cells were collected, lysed, quantified and run. After the
run, the membrane was transferred and the primary
antibody, p-EF2 was applied to measure the down
regulation of EF2K activity.

Western Blot
On reading the membrane gotten from the gel electrophoresis, the hypothesis was seen to be
true. With increased concentration of Thymoquinone, the expression of p-EF2, a marker to
test whether EF2K activity had reduced, was seen to decrease. This can be seen in Figure
2.This shows that Thymoquinone could possibly serve as novel drug in combatting
pancreatic cancer by decreasing its proliferation by EF2K. Figure 3 shows that
Thymoquinone inhibits EF2K activity and not EF2K directly. This is shown by the constant
band of EF2K along the increasing Thymoquinone concentration.
Figure 2 : Down Regulation of
p-EF2 with increasing
Concentration
of Thymoquinone
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Figure 3: Western Blot of
EF2K. Constant amount of
EF2K with increasing
concentration of
Thymoquinone

Clonogenic Asay
In a 6-well plate, 1000 Panc-1 cells were seeded in 2ml of
media. These cells were left for 48 hours before being
treated with Thymoquinone of concentrations, 2.5uM,
5uM, 7.5uM and 10uM with 2 additional controls, one
well left untreated and one well of 1mL of DMSO. 9 days
after treatment, the cells were stained and checked for
decrease in cell proliferation.
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Figure 4:
Densitometric Analysis of pEF2 down regulation
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